Hutchison Chi-Med shares up on updated results from 'CALYPSO'
10th Feb 2020 07:36
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.
Read moreHutchison Chi-Med upbeat on progress with surufatinib
20th Jan 2020 16:00
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.
Read moreHutchison Chi-Med gets priority review for 'surufatinib' in China
20th Dec 2019 15:48
(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.
Read moreHutchison China Meditech expands collaboration with Innovent
10th Oct 2019 15:45
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
Read moreHutchison Chi-Med initiates latest study of HMPL-523
4th Oct 2019 15:21
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.
Read moreHutchison China MediTech launches trial for autoimmune disorder treatment
23rd Aug 2019 11:25
(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.
Read moreHutchison Chi-Med makes progress with surufatinib
14th Jun 2019 14:40
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.
Read moreHutchison loss widens as China legislation hampers revenue
11th Mar 2019 11:54
(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.
Read moreHutchison Chi-Med enters four new drug test collaborations
29th Nov 2018 12:17
(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.
Read moreHutchison China MediTech presents promising data in Washington
14th Nov 2016 11:11
(ShareCast News) - Hutchison China MediTech presented data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics and pharmacodynamics of single and multiple doses of HMPL-523 on Monday, to the Annual Meeting of the American College of Rheumatol
Read moreHutchison China's JV receives $60m land compensation
31st Oct 2016 10:05
(ShareCast News) - Hutchison China MediTech's prescription drug joint-venture received $59.5m on Friday from the Shanghai government under its land compensation agreement. The joint-venture with a subsidiary of Shanghai Pharmaceuticals, Shanghai Hutchison Pharmaceuticals, entered into a compensation
Read moreDirector dealings: Chi-Med director's wife bags a bargain?
9th Aug 2016 15:41
(ShareCast News) - The wife of Hutchison China MediTech (Chi-Med) director Christopher Nash has swooped into the market to pick up a few of the company's shares a after hearing good reports on the China-based biopharma outfit's recent interim results and bulging drug pipeline. Mrs Nash, wife of the
Read moreChi-Med revenue ahead, but investments kill most income
2nd Aug 2016 16:19
(ShareCast News) - Hutchison China MediTech reported its interim results for the six months to 30 June on Tuesday, with group revenue up 27% to $104.5m, from $82.5m. The AIM-traded firm said net income attributable to Chi-Med was $0.5m, significantly down from $15.9m a year ago, reflecting a sharp i
Read moreChi-Med expands TATTON Phase II trial
20th Jun 2016 15:26
(ShareCast News) - Healthcare group Hutchison China MediTech (Chi-Med) announced on Monday the start of a Phase II expansion of its ongoing TATTON trial. The AIM-traded firm said the TATTON trial is evaluating the selective c-Met inhibitor savolitinib in epidermal growth factor receptor (EGFR) mutan
Read moreChi-Med launches fruquintinib trial in China
13th May 2016 16:27
(ShareCast News) - Hutchison China MediTech announced on Friday that it has completed patient enrolment of FRESCO, its Phase III trial of fruquintinib in third-line locally advanced or metastatic colorectal cancer in China. The AIM-traded company said more than 300,000 new cases of CRC were diagnose
Read more